Frontlight ResearchEarly access
Haemophilia trials in Germany
16 of 29 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 4Taking peopleNuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- Where
- Berlin, Duisburg, Hamburg
- Age
- 12 years and over
- People
- 28 worldwide
- Run by
- Octapharma
See details and how to joinNCT05935358 - Phase 4Taking peopleNuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- Where
- Bonn, Duisburg, Hamburg
- Age
- 12 years and over
- People
- 28 worldwide
- Run by
- Octapharma
See details and how to joinNCT05936580 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Where
- Berlin, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover
- Age
- 12 years and over
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00 - Phase 3Taking peopleA Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
- Where
- Berlin, Bonn, Hanover, Leipzig, Regensburg
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07830732 · EU 2026-525529-19-00 - Phase 3Taking peopleEfanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining
- Where
- Berlin, Bonn, Dresden, Duisburg, Frankfurt am Main, Frankfurt Am Main, Giessen, Hamburg, Hanover, Homburg, Kiel, Leipzig, Regensburg
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- GWT-Tud GmbH
See details and how to join2025-523896-44-00 - Phase 3Not yet taking people in GermanyA Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
- Where
- Munich
- Age
- 1 year to 11 years
- People
- 85 worldwide
- Run by
- Sanofi
See details and how to joinNCT07285460 · EU 2025-521858-42-00 - Phase 3CompletedOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Where
- Berlin
- Age
- 1 year to 74 years
- People
- 245 worldwide
- Run by
- Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Where
- Berlin, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hanover
- Age
- 12 years and over
- People
- 138 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00 - Phase 3Taking peopleA Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
- Where
- Berlin, Bonn
- Age
- 18 years to 64 years
- People
- 32 worldwide
- Run by
- Pfizer Inc.
See details and how to join2025-523660-21-00 - Phase 1/2Taking peopleA Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Where
- Bonn, Frankfurt Am Main, Hamburg
- Age
- 2 years and over
- People
- 130 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06379789 · EU 2023-507260-40-00 - Phase 3CompletedA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Where
- Berlin
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00 - Phase 3Taking peopleSafety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Where
- Bonn
- Age
- 18 years and over
- People
- 173 worldwide
- Run by
- Pfizer
See details and how to joinNCT05568719 - Phase 1CompletedA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
- Where
- Berlin, Bonn, Hanover
- Age
- 18 years to 64 years
- People
- 30 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00 - Phase 4Taking peopleNuwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-label, Non-controlled study (NuDIMENSION)
- Where
- Bonn, Hamburg
- People
- 17 worldwide
- Run by
- Octapharma AG
See details and how to join2022-502061-17-00 - No phaseEnrolling by invitationFeasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia
- Where
- Bonn
- Age
- 18 years and over
- People
- 12
- Run by
- University Hospital, Bonn
See details and how to joinNCT07259356 - Phase 4Taking peopleNuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER)
- Where
- Berlin, Hamburg
- People
- 45 worldwide
- Run by
- Octapharma AG
See details and how to join2022-502060-21-00